These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 2156154

  • 1. Role of the incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine and its carbocyclic analogue into DNA of herpes simplex virus type 1-infected cells in the antiviral effects of these compounds.
    Balzarini J, Bernaerts R, Verbruggen A, De Clercq E.
    Mol Pharmacol; 1990 Mar; 37(3):402-7. PubMed ID: 2156154
    [Abstract] [Full Text] [Related]

  • 2. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
    Balzarini J, De Clercq E, Verbruggen A, Ayusawa D, Shimizu K, Seno T.
    Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
    [Abstract] [Full Text] [Related]

  • 3. Incorporation of carbocyclic (E)-5-(2-iodovinyl)-2'-deoxyuridine (C-IVDU) into DNA of herpes simplex virus-infected cells.
    Bernaerts R, De Clercq E, Balzarini J, Herdewijn P, Verbruggen A.
    Antiviral Res; 1985 Sep; Suppl 1():51-6. PubMed ID: 3002266
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.
    Yokota T, Konno K, Shigeta S, Verbruggen A, De Clercq E.
    Mol Pharmacol; 1987 May; 31(5):493-9. PubMed ID: 3033468
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synthesis and cellular uptake of 2'-substituted analogues of (E)-5-(2-[125I]iodovinyl)-2'-deoxyuridine in tumor cells transduced with the herpes simplex type-1 thymidine kinase gene. Evaluation as probes for monitoring gene therapy.
    Morin KW, Atrazheva ED, Knaus EE, Wiebe LI.
    J Med Chem; 1997 Jul 04; 40(14):2184-90. PubMed ID: 9216837
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selective antiherpetic activity of carbocyclic analogues of (E)-5-(2-halogenovinyl)-2'-deoxyuridines: dependence on specific phosphorylation by viral thymidine kinase.
    De Clercq E, Balzarini J, Bernaerts R, Herdewijn P, Verbruggen A.
    Biochem Biophys Res Commun; 1985 Jan 16; 126(1):397-403. PubMed ID: 2982373
    [Abstract] [Full Text] [Related]

  • 12. Increased sensitivity of thymidine kinase-deficient (TK-) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds.
    Balzarini J, De Clercq E, Verbruggen A, Crumpacker C, Ayusawa D, Seno T.
    Anticancer Res; 1986 Jan 16; 6(5):1077-84. PubMed ID: 2432829
    [Abstract] [Full Text] [Related]

  • 13. Specific phosphorylation of 5-ethyl-2'-deoxyuridine by herpes simplex virus-infected cells and incorporation into viral DNA.
    De Clercq E, Bernaerts R.
    J Biol Chem; 1987 Nov 05; 262(31):14905-11. PubMed ID: 2822705
    [Abstract] [Full Text] [Related]

  • 14. Metabolic competition studies of 2'-fluoro-5-iodo-1-beta-d-arabinofuranosylcytosine in vero cells and herpes simplex type 1-infected vero cells.
    Chou TC, Lopez C, Colacino JM, Feinberg A, Watanabe KA, Fox JJ, Philips FS.
    Mol Pharmacol; 1984 Nov 05; 26(3):587-93. PubMed ID: 6092904
    [Abstract] [Full Text] [Related]

  • 15. The incorporation of 5-iodo-5'-amino-2',5-dideoxyuridine and 5-iodo-2'-deoxyuridine into herpes simplex virus DNA. Relationship between antiviral activity and effects on DNA structure.
    Fischer PH, Chen MS, Prusoff WH.
    Biochim Biophys Acta; 1980 Feb 29; 606(2):236-45. PubMed ID: 6243982
    [Abstract] [Full Text] [Related]

  • 16. Novel (E)-5-(2-iodovinyl)-2'-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors.
    Balzarini J, Morin KW, Knaus EE, Wiebe LI, De Clercq E.
    Gene Ther; 1995 Jul 29; 2(5):317-22. PubMed ID: 7671107
    [Abstract] [Full Text] [Related]

  • 17. [Hevizos ointment efficacy in view of molecular pharmacology].
    Otvös L, Tüdös FH.
    Acta Pharm Hung; 1993 Jul 29; 63(4):237-42. PubMed ID: 8397468
    [Abstract] [Full Text] [Related]

  • 18. Incorporation of E-5-(2-halovinyl)-2'-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1-infected cells.
    Allaudeen HS, Chen MS, Lee JJ, De Clercq E, Prusoff WH.
    J Biol Chem; 1982 Jan 25; 257(2):603-6. PubMed ID: 6274855
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E)-5-(2-halovinyl)-2'-deoxycytidines.
    Herdewijn P, De Clercq E, Balzarini J, Vanderhaeghe H.
    J Med Chem; 1985 May 25; 28(5):550-5. PubMed ID: 2985782
    [Abstract] [Full Text] [Related]

  • 20. Differential inhibition of herpes simplex viruses, type 1 (HSV-1) an type 2 (HSV-2), by (E)-5-(2-X-vinyl)-2'-deoxyuridines.
    de Clercq E, Verhelst G, Descamps J, Bergstrom DE.
    Acta Microbiol Acad Sci Hung; 1981 May 25; 28(3):307-12. PubMed ID: 6272553
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.